Steven O’Day: The research we shared underscores BOT’s broad potential utility across multiple advanced solid tumors

Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn:

“It was an exciting weekend for me and for Agenus at the European Society for Medical Oncology Conference in Madrid. I always enjoy reconnecting with my peers and learning about the latest innovations that are shaping new and important ways we can combat cancer.

Agenus announced new and updated data from our ongoing investigational botensilimab/balstilimab (BOT/BAL) clinical programs. The research we shared underscore BOT’s broad potential utility across multiple advanced solid tumors—spanning colorectal, pancreatic, and lung cancers as well as melanoma and sarcoma. The data highlight BOT’s potential beyond first-generation immunotherapy and current treatment norms.

We also shared some impressive neoadjuvant data in microsatellite stable colorectal cancer from an investigator sponsored study, which offers an opportunity to expand our research of BOT into early-stage cancers.

Check out the highlights here.

And for a deep dive, listen to the webcast of the panel of experts, Alexander Eggermont, Manuel Hidalgo Medina, Marwan Fakih, Pashtoon Kasi, and Breelyn Wilky. ”

For the webcast click here.
Source: Steven O’Day/LinkedIn